Krystal Biotech, Inc.
Developing redosable gene therapies for rare diseases using a modified HSV-1 vector.
KRYS | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 2100 WHARTON STREET, 15203 PITTSBURGH
- Website:
- https://www.krystalbio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, and commercializing genetic medicines for severe, life-threatening, and rare diseases with high unmet medical needs. The company's proprietary platform develops redosable gene therapies using a modified herpes simplex virus type 1 (HSV-1) vector. Its mission is to provide treatments for conditions with limited or no approved therapies, including an FDA-approved therapy for Dystrophic Epidermolysis Bullosa (DEB).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Krystal Biotech, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Krystal Biotech, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Krystal Biotech, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
